ArticleInternational journal of hematology2026
Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilms tumor gene 1 (WT1) is frequently identified in hematologic malignancies; however, its utility for measurable residual disease (MRD) assessment remains controversial. We investigated the prognostic impact of WT1 dynamics in peripheral blood (PB) before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
methodsOf 85 patients with AML or MDS who underwent allo-HSCT at our institution between January 2016 and March 2025, 51 who had WT1 in PB assessed before and approximately 100 days after transplantation were analyzed retrospectively. Patients were stratified by WT1 status before and/or after allo-HSCT. WT1 expression < 50 copies/µg RNA was defined as MRD-negative.
resultsIn univariate analysis, 2-year progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) differed significantly between Group A (MRD-/MRD-), Group B (MRD+/MRD-), and Group C (MRD+/MRD+) (PFS: 93.8% vs 67.0% vs 31.2%; OS: 93.8% vs 85.4% vs 48.6%; CIR: 0% vs 28.2% vs 68.7%). In multivariate analysis, conversion from WT1 positivity to negativity after allo-HSCT was associated with a favorable prognosis. No patients who were WT1-negative before allo-HSCT relapsed in this cohort.
conclusionWT1 status before and after allo-HSCT is a relevant prognostic marker.
Indexed as
Identifiers
42268480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.